Vascular Biogenics Ltd (VBLT)

[gr8db8]

Some key points, including the first patient has been dosed in the Company's GLOBE Study:

1) (most promising) "FDA encouraged VBL to launch this single needed pivotal Phase 3 trial for registration even prior to the completion of an ongoing Phase 2 trial ... FDA decision in 2014 was derived from the promising data of an early interim analysis from our ongoing Phase 2 study of VB-111 in rGBM. Later analyses demonstrated even longer overall survival benefit along with statistical significance"

2) Overall survival has increased from 414 days to 480 days in Phase 2

3) "studied VB-111 in over 170 patients" -- Phase 3 is for 252 patients - only 80 more than what has been studied.

You put this all together and VB-111 on its own is a very promising drug. Let's see what it does in Thyroid and Ovarian.

References:
1) http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2080921
2) http://ir.vblrx.com/phoenix.zhtml?c=253311&p=irol-newsArticle&ID=2079383
3) http://www.vblrx.com/cancer-programs/overview/